5 completed, 3 terminated. 7 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Terminated 3 |
| Phase 3 | 2 | Terminated 2 |
| Phase 1 | 1 | Completed 1 |
Follow Addex Pharma S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Open-label Safety Study of Dipraglurant (ADX48621) in Patients With Parkinson's Disease Receiving Levodopa-based Therapy Dipraglurant - Parkinson Disease, Dyskinesia, Drug-Induced | Phase 2 / Phase 3 | Terminated | Addex Pharma S.A. | 17 | 2021-10-25 | 2025-08-06 |
| Exploratory Study of Dipraglurant (ADX48621) for the Treatment of Patients With Blepharospasm Dipraglurant, Placebo - Blepharospasm, Dystonia | Phase 2 | Completed | Addex Pharma S.A. | 15 | 2021-10-06 | 2025-10-03 |
| Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy Dipraglurant, Placebo - Parkinson Disease, Dyskinesia, Drug-Induced | Phase 2 / Phase 3 | Terminated | Addex Pharma S.A. | 25 | 2021-08-06 | 2025-08-06 |
| PET Imaging Study to Evaluate the mGlu5r Occupancy Following ADX48621 (Dipraglurant) Administration ADX48621, [18F]FPEB - Healthy | Phase 1 | Completed | Johns Hopkins University | 12 | 2015-04-01 | 2018-08-17 |
| ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease ADX48621, Placebo - Parkinson's Disease | Phase 2 | Completed | Addex Pharma S.A. | 83 | 2011-04-01 | 2012-07-16 |
| ADX10059 Migraine Prevention Study ADX10059, ADX10059 Matching Placebo - Migraine | Phase 2 | Terminated | Addex Pharma S.A. | 350 | 2008-12-01 | 2009-12-24 |
| ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD) ADX10059, ADX10059 Matching Placebo - Gastroesophageal Reflux | Phase 2 | Completed | Addex Pharma S.A. | 120 | 2008-12-01 | 2009-12-24 |
| ADX10059 as an add-on Therapy to Proton Pump Inhibitors (PPIs) in Patients With Gastroesophageal Reflux (GERD) ADX10059, ADX10059 Matching Placebo - Gastroesophageal Reflux | Phase 2 | Completed | Addex Pharma S.A. | 298 | 2008-12-01 | 2012-07-16 |
Dyskinesias (3) · Parkinson Disease (3) · Dyskinesia, Drug-Induced (2) · Gastroesophageal Reflux (2) · Heartburn (2) · Blepharospasm (1) · Dystonia (1) · Epilepsy (1) · Migraine Disorders (1)
6-fluoro-2-(4-(pyridin-2-yl)but-3-yn-1-yl)imidazo(1,2-a)pyridine (5)
United States (6) · France (4) · Germany (4) · Austria (3) · Belgium (2) · Netherlands (1) · Switzerland (1) · United Kingdom (1)
PMID 21320138, PMID 31356217, PMID 38310362
2008 (3)